drugset / Trial / NCT07582874

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

NCT07582874 ↗

Expanded access Available Amylyx Pharmaceuticals Inc.

Summary

The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored during this program.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Avexitide Peptide 90 mg Subcutaneous